Fig. 6

HOXB2 promotes the proliferation and cisplatin resistance of OV cells via DANCR. A–B. qPCR results showing the mRNA levels of the target genes. C. Relative cell viability of shNC + Vector, shNC + DANCR, shHOXB2 + Vector, and shHOXB2 + DANCR cell groups. Statistical significance was calculated using two-way ANOVA. D. Relative cell viability of shNC + Vector, shNC + DANCR, shHOXB2 + Vector, shHOXB2 + DANCR cells at different concentrations of CDDP. E. Colony formation assays of shNC + Vector, shNC + DANCR, shHOXB2 + Vector, shHOXB2 + DANCR cells treated with CDDP (10 µM for A2780/DDP, 5 µM for OV8) and equal PBS. The P-value between the two groups was calculated using an unpaired t-test. F. Apoptotic assay of siNC + Vector, siNC + DANCR, siHOXB2 + Vector, siHOXB2 + DANCR cells after treatment of CDDP (20 µM for A2780/DDP, 10 µM for OV8) and equal PBS for 24 h. The P-value between the two groups was calculated using an unpaired t-test. G. Western blotting showed the target protein level of shNC + Vector, shNC + DANCR, shHOXB2 + Vector, shHOXB2 + DANCR cells after treatment of CDDP (20 µM for A2780/DDP, 10 µM for OV8) for 48 h. *P < 0.05, **P < 0.01, ***P < 0.001, ***P < 0.0001